Hyperkalemia in the Hypertensive Patient

Current Cardiology Reports
Jay Ian Lakkis, Matthew R Weir

Abstract

Hyperkalemia develops in a patient with systemic arterial hypertension (HTN) if one or more risk factors are present, namely chronic kidney disease (CKD) (especially severe stage 4-5 CKD), diabetes mellitus (DM), heart failure (HF), or pharmacological therapies that interfere with potassium homeostasis, mainly through renin-angiotensin-aldosterone inhibition (RAASi). Hyperkalemia is a considerable reason of morbidity (emergency department (ED) visits and hospitalizations) and portends a higher mortality risk in patients at risk; for instance, hyperkalemia increases the risk of mortality within 1 day of a hyperkalemic event. This review aims to identify the risk factors for high-serum potassium, highlight the risk versus benefit of RAASi in certain patient populations, and outline preventive as well as therapeutic strategies for hyperkalemia. A growing body of evidence supports the safety and efficacy of cation-exchange resins, patiromer, or sodium zirconium cyclosilicate, in patients with a compelling indication for RAASi, yet in whom such therapy was complicated by hyperkalemia, allowing these patients to benefit from continued RAASi therapy. In summary, novel cation exchange polymers present the clinician with a new and safe ...Continue Reading

References

Dec 1, 1979·The Journal of Clinical Investigation·W B CampbellH D Itskovitz
Aug 1, 1991·The New England Journal of Medicine·UNKNOWN SOLVD InvestigatorsJay N Cohn
Jan 1, 1990·The Journal of Diabetic Complications·J UribarriH J Carroll
Nov 1, 1990·Kidney International·M Allon, C Copkney
Mar 15, 1989·Annals of Internal Medicine·M AllonC Copkney
Jan 1, 1987·American Journal of Nephrology·A H Tzamaloukas, P S Avasthi
Aug 1, 1986·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·R S MartinJ P Hayslett
Sep 21, 1972·The New England Journal of Medicine·M SchambelanE G Biglieri
May 1, 1973·The Journal of Clinical Endocrinology and Metabolism·P WeidmannS G Massry
Dec 1, 1983·The Tohoku Journal of Experimental Medicine·M ShibataH Iwata
Jun 1, 1995·The American Journal of Medicine·J R OsterL M Fishman
Nov 13, 1998·The New England Journal of Medicine·G Remuzzi, T Bertani
Oct 8, 1999·The New England Journal of Medicine·E Ritz, S R Orth
Mar 30, 2000·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·M A Perazella
Jun 1, 2000·Southern Medical Journal·A DardikM G Harrison
Sep 22, 2001·The New England Journal of Medicine·E J LewisUNKNOWN Collaborative Study Group
Sep 22, 2001·The New England Journal of Medicine·B M BrennerUNKNOWN RENAAL Study Investigators
Sep 22, 2001·The New England Journal of Medicine·H H ParvingUNKNOWN Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group
Apr 17, 2002·Annals of Internal Medicine·Giuseppe RemuzziNorberto Perico
Aug 7, 2002·Circulation·Giancarlo VibertiUNKNOWN MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators
Aug 23, 2002·Journal of the American Society of Nephrology : JASN·Olivier Bonny, Bernard C Rossier
Apr 2, 2003·The New England Journal of Medicine·Bertram PittUNKNOWN Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators
Oct 2, 2003·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Garabed EknoyanRobert Toto
Jul 31, 2004·Journal of the American Society of Nephrology : JASN·Michael G ShlipakHarlan M Krumholz
Oct 19, 2004·Journal of the American College of Cardiology·Justin EzekowitzUNKNOWN APPROACH Investigators
Feb 11, 2005·Clinical and Experimental Hypertension : CHE·Lewis Landsberg, Mark Molitch
Mar 18, 2005·The Journal of Pathology·T MathialahanG I Sandle
Jan 13, 2006·The New England Journal of Medicine·Fan Fan HouRen Wen Geng
Feb 8, 2006·Circulation·Hans L HillegeDirk J van Veldhuisen
May 16, 2006·Journal of the American College of Cardiology·Grace L SmithHarlan M Krumholz
Jun 23, 2006·Journal of the American Society of Nephrology : JASN·Stein I HallanJostein Holmen
Sep 19, 2006·The New England Journal of Medicine·UNKNOWN DREAM Trial InvestigatorsRury R Holman

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Related Papers

Current Opinion in Nephrology and Hypertension
Andrea C J CowanMatthew R Weir
Journal of the American College of Cardiology
Chaudhry M S SarwarJaved Butler
Wiadomości lekarskie : organ Polskiego Towarzystwa Lekarskiego
Tomasz Głogowski, Ewa Wojtaszek
Journal of Pharmacy Practice
Antony Q PhamTimothy Nguyen
© 2022 Meta ULC. All rights reserved